PMID- 31303766
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200929
IS  - 1178-6930 (Print)
IS  - 1178-6930 (Electronic)
IS  - 1178-6930 (Linking)
VI  - 12
DP  - 2019
TI  - The safety and efficacy of amrubicin in the treatment of previously untreated 
      extensive-disease small-cell lung cancer: a meta-analysis.
PG  - 5135-5142
LID - 10.2147/OTT.S200601 [doi]
AB  - Background: Extensive-disease small-cell lung cancer (ED-SCLC) has been known to 
      be rapid progression and relapse, despite highly sensitive to chemotherapy. 
      Amrubicin (AMR), a third-generation synthetic anthracycline, was accepted as a 
      feasible alternative compared with the standard first-line chemotherapy for 
      previously untreated ED-SCLC. While, the efficacies of these amrubicin-based 
      regimens are unsatisfactory. Aim: Our meta-analysis was performed to assess the 
      efficacy and toxicity of first-line therapy comparing AMR and chemotherapy in 
      patients with ED-SCLC. Methods: Electronic databases were searched for eligible 
      trials updated on November 2018. Randomized-controlled trials assessing the 
      efficacy and safety of AMR in ED-SCLC were included, of which the interested 
      results were objective response rate (ORR), progression-free survival (PFS), 
      overall survival (OS), and adverse events (AEs). Results: A total of 6 randomized 
      controlled trials were included in this analysis. There are no significant 
      differences in OS (OR=1.03, 95% CI=0.66-1.60, P=0.91), PFS (OR=1.2, 95% 
      CI=10.77-1.88, P=0.41) or ORR (OR=1.31, 95% CI=0.90-1.92, P=0.16) with AMR 
      (OR=0.90, 95% CI=0.76-1.05, P=0.17). The most common treatment-related AEs in the 
      AMR group are leukopenia (OR=3.13, 95% CI=1.22-7.99, P=0.02) and neutropenia 
      (OR=3.25, 95% CI=1.38-7.65, P=0.007). Fatigue, anemia, nausea, vomiting, diarrhea 
      the difference between the two groups had no statistical significance. 
      Conclusion: The results of our analysis indicated that AMR therapy demonstrated 
      non-inferiority to the standard first-line chemotherapy for previously untreated 
      ED-SCLC. Whether it can be accepted as an alternative regimen to the standard 
      first-line chemotherapy is still warranted.
FAU - Wu, Ji-Feng
AU  - Wu JF
AD  - Department of Respiratory Medicine, Jiangxi Province Hospital of Integrated 
      Chinese & Western Medicine, Nanchang, Jiangxi, People's Republic of China.
FAU - Zhou, Jian-Jun
AU  - Zhou JJ
AD  - Department of Respiratory Medicine, Jiangxi Province Hospital of Integrated 
      Chinese & Western Medicine, Nanchang, Jiangxi, People's Republic of China.
FAU - Li, Xin-Ai
AU  - Li XA
AD  - Department of Respiratory Medicine, Jiangxi Province Hospital of Integrated 
      Chinese & Western Medicine, Nanchang, Jiangxi, People's Republic of China.
FAU - Hu, Li-Hui
AU  - Hu LH
AD  - Department of Respiratory Medicine, Jiangxi Province Hospital of Integrated 
      Chinese & Western Medicine, Nanchang, Jiangxi, People's Republic of China.
FAU - Wen, Meng-Li
AU  - Wen ML
AD  - Department of General surgery, The Fourth Affiliated Hospital of Nanchang 
      University, Nanchang, Jiangxi, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20190701
PL  - New Zealand
TA  - Onco Targets Ther
JT  - OncoTargets and therapy
JID - 101514322
PMC - PMC6611712
OTO - NOTNLM
OT  - amrubicin
OT  - extensive-disease
OT  - meta-analysis
OT  - small-cell lung cancer
COIS- The authors report no conflicts of interest in this work.
EDAT- 2019/07/16 06:00
MHDA- 2019/07/16 06:01
PMCR- 2019/07/01
CRDT- 2019/07/16 06:00
PHST- 2019/01/06 00:00 [received]
PHST- 2019/05/14 00:00 [accepted]
PHST- 2019/07/16 06:00 [entrez]
PHST- 2019/07/16 06:00 [pubmed]
PHST- 2019/07/16 06:01 [medline]
PHST- 2019/07/01 00:00 [pmc-release]
AID - 200601 [pii]
AID - 10.2147/OTT.S200601 [doi]
PST - epublish
SO  - Onco Targets Ther. 2019 Jul 1;12:5135-5142. doi: 10.2147/OTT.S200601. eCollection 
      2019.